As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
Aims and scope
Allergy, Asthma & Clinical Immunology (AACI), the official journal of the Canadian Society of Allergy and Clinical Immunology (CSACI), is an open access journal that encompasses all aspects of diagnosis, epidemiology, prevention and treatment of allergic and immunologic disease.
AACI reports on basic research and clinically applied studies in the following areas and other related topics: asthma and occupational lung disease, rhinoconjunctivitis and rhinosinusitis, drug hypersensitivity, allergic skin diseases, urticaria and angioedema, venom hypersensitivity, anaphylaxis and food allergy, immunotherapy, immune modulators and biologics, immune deficiency and autoimmunity, T cell and B cell functions, regulatory T cells, natural killer cells, mast cell and eosinophil functions, complement abnormalities.
Richard Warrington, University of Manitoba, Canada
Harold Kim, University of Western Ontario & McMaster University, Canada
Rajesh Kumar, Ann & Robert H. Lurie Children's Memorial Hospital, USA
Jean Marshall, Dalhousie University, Canada
Harissios Vliagoftis, University of Alberta, Canada
Wade Watson, Dalhousie University, Canada
Highlighting the key milestones and achievements in Allergy, Asthma and Clinical Immunology, this timeline takes a journey of the past 10 open access years.
From the most mentioned research article to the latest practical guides in allergy and immunology in Canada, this infographic celebrates the impact of the journal's content from 2009-2019. With nearly 6,000 online mentions, and a monthly average of 70,000 accesses and downloads, AACI continues to be a high-visibility forum for new insights and discussions within the allergy and clinical immunology research community for the next 10 years and beyond.
A large, downloadable version of the infographic is available here.
About the CSACI
AACI is the official journal of the Canadian Society of Allergy and Clinical Immunology (CSACI). The CSACI is the largest national professional medical specialty organization in Canada representing allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic diseases.
The CSACI was founded in 1945 to fulfill the following goals: improving the standards of teaching and the practice of allergy and clinical immunology; fostering co-operation between those engaged in the study and practice of allergy and clinical immunology; encourage research in the field of allergy and clinical immunology.
The CSACI represents over 475 (Canadian and international) members who are from all parts of the country including rural areas, cities, community hospitals and academic university teaching centres. The CSACI remains committed to supporting allergists and clinical immunologists in maintaining the pre-eminence of both research and education in Canada. Moving forward, the CSACI will support these aims to ensure that high quality health care is available to all our patients throughout our communities.
Professor Richard Warrington
Dr Warrington is Professor and Head of Allergy and Clinical Immunology at the University of Manitoba in Winnipeg, Canada. He received his medical degree from the Royal London Hospital, London, England in 1968, and moved to St John’s, Newfoundland in 1969 to help found the new Medical School at Memorial University. He received his PhD in immunology from Memorial University, in 1973. He trained in allergy & clinical immunology at the University of Manitoba until 1976, when he joined the Section of Allergy & Clinical Immunology in the Department of Medicine, which he has headed since 1982. From 1983 to 1996, Dr Warrington directed the Rheumatic Disease Unit Research Laboratory at the University of Manitoba.
The official journal of CSACI
Annual Journal Metrics
96 days to first decision for reviewed manuscripts only
89 days to first decision for all manuscripts
172 days from submission to acceptance
18 days from acceptance to publication
735 Altmetric mentions